Cantor Fitzgerald Maintains Overweight on Insmed, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Jennifer Kim maintains an Overweight rating on Insmed (NASDAQ:INSM) and raises the price target from $46 to $54.
September 21, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Insmed and raised the price target from $46 to $54, indicating a positive outlook for the stock.
The raised price target by Cantor Fitzgerald indicates a positive outlook for Insmed. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100